hat
Swanton, ki gen etid parèt nan Syans, espere ke yo lanse premye jijman imen an nan pasyan kansè nan poumon nan pwochen de a twa ane yo. Maladi a se UK a nan pi gwo asasen kansè, reklame plis pase 35,000 ap viv yon ane. Li se klè si wi ou non tretman an pral travay, men syantis kwè li gen yon pi bon chans si sistèm iminitè a vize drapo miltip sou yon timè. "Nou pa te pwouve ke sa a ka gen enpak sou sou swen pasyan. Ki sa nou yo te montre se ke gen terapi inik potansyèlman prezan nan timè chak pasyan an,"Swanton di. "Sa a se pran medikaman pèsonalize nan limit absoli li yo."
eng
Swanton, whose study appears in Science, hopes to launch the first human trial in lung cancer patients in the next two to three years. The disease is the UK’s biggest cancer killer, claiming more than 35,000 lives a year. It is unclear whether the treatment will work, but scientists believe it has a better chance if the immune system targets multiple flags on a tumour. “We haven’t proved that this can impact on patient care. What we have shown is that there are unique therapies potentially present within each patient’s tumour,” Swanton said. “This is taking personalised medicine to its absolute limit.”